Biopharma · FDA Approvals · Stock

ELOX Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, th…

Assets on file: exaluren

Start live analysis of ELOX Run 8-agent AI analysis Stock overview All sector events →

Catalyst calendar

Dated catalysts for ELOX, including recently decided ones.

June 2027

Jun 2027

Jun 30, 2027

in 287 days

ELOXEloxx Pharmaceuticals, Inc.

exaluren: Phase 2 trial NCT07523581 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Recent first-hand events

Every first-hand event for ELOX, newest first.

Instant stream — events appear as soon as they are filed.

Notable

Aug 11, 2026

09:19 PM

ELOXEloxx Pharmaceuticals, Inc.

Eloxx: EC grants orphan designation for exaluren in ADPKD

The European Commission granted orphan medicinal product designation for exaluren in ADPKD. This designation adds to the existing FDA orphan drug designation for Alport syndrome and supports the planned Phase 2 trial initiation in nonsense mutation ADPKD in 2027.

FDA designationSEC 8-K